Drug
Chf5633
Chf5633: highest development phase Phase 2, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF5633 NCT02452476 | Phase 2 | Respiratory Distress Syndrome, Newborn |
Latest
No recent events.
Follow Chf5633 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.